Einrichtungen, die zum Universitätsklinikum Erlangen gehören

Access to patients for rheumatology research: are large patient organisations still the primary gateway to patients? Insights from an online survey of 2050 responses (2026) Bartsch V, Schett G, Hueber AJ Journal article Genetic testing in adults with CKD of unknown cause: From unknown to diagnosed Genetische Testung bei Erwachsenen mit CKD unklarer Ursache: Von unbekannt zu diagnostiziert (2026) Hilger A Journal article Challenges of Standard Pediatric Epilepsy Monitoring and the Potential Benefits of Contactless Sensor Technologies: Exploratory Qualitative Study (2026) Öhl N, Strack D, Kusnik S, Link I, Hofmann M, Steigleder T, Weisser A, et al. Journal article STEMI caused by spontaneous coronary artery dissection: prevalence, patient characteristics and outcomes (2026) Malleier S, Gaede L, Jung S, Marwan M, Achenbach S, Tröbs M Journal article Game of microbes: a wildling's guide (2026) Bruno P, Rosshart SP Journal article, Review article Correction: Comprehensive analysis of CNOT3-related neurodevelopmental disorders: phenotypic and genotypic characterization (European Journal of Human Genetics, (2025), 33, 8, (989-996), 10.1038/s41431-025-01884-z) (2026) Engel C, Rendek M, Assoumani J, Argilli E, Ariani F, Avice-Denizet AL, Bijlsma EK, et al. Journal article, Erratum Correction: ISCEV extended protocol for the photoreceptor directed ERG using full-field silent substitution stimuli (Documenta Ophthalmologica, (2026), 10.1007/s10633-026-10087-w) (2026) Kremers J, Barboni MT, Zele AJ, Feigl B, McAnany JJ, Robson AG, Nagy BV, et al. Journal article, Erratum Intelligent histology for tumor neurosurgery (2026) Hou X, Kondepudi AV, Jiang C, Lyu Y, Harake ES, Chowdury A, Meißner AK, et al. Journal article, Review article Prognostic value of the tumor immune microenvironment, PD-L1 and p16INK4A in penile squamous cell carcinoma (2026) Fiegl A, Angeloni M, Mink J, Pryalukhin A, Khalmurzaev O, Lohse S, Lobo J, et al. Journal article Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target (2026) Luning R, Maas SL, French PJ, Hoogstrate Y, van Hijfte L, Head R, de Heer I, et al. Journal article